摘要
目的:观察米非司酮联合米索前列醇治疗子宫内膜不典型增生(AEH)的疗效及安全性。方法:68例AEH患者随机分为观察组与对照组各34例。观察组予以米非司酮片150 mg,每3 d一次,服用米非司酮片48 h后加用米索前列醇片0.6 mg;对照组予以甲羟孕酮片30 mg,qd。两组均以6d为1周期,连用12个周期,观察治疗前后子宫内膜厚度变化,比较两组疗效及药品不良反应。结果:治疗12周期后,两组患者子宫内膜厚度均较治疗前有改善(P<0.01),且观察组改善幅度明显优于对照组(P<0.01)。观察组临床总有效率明显优于对照组(P<0.05),且药品不良反应发生率低于对照组(P<0.05)。结论:米非司酮联合米索前列醇治疗AEH安全、有效。
Objective ： To observe the curative effect and safety of mifepristone combined with misoprostolin in the treatment of 34 cases of atypical endometrium hyperplasia （AEH）. Methods： Totally 68 cases of AEH were selected and divided into the observation group and the control group randomly with 34 cases eachl The patients in the observation group were given 150rag mifepristone tablets once for every 3 days, and 0.6rag misoprostoI 48h after the mifepristone administration. The patients in the control group were given 30rag medroxyprogesterone acetate tablets qd. One course of treatment was 6 days and the treatment was lasted 12 eycles. The changes in endometrial thickness before and after the medical treatment were observed, and the curative effect and adverse drug reactions （ADR） of patients in the two groups were compared as well. Results： After the 12-cycle medical treatment, the endometrial thickness of patients in the two groups was much improved than before （P 〈 0.01 ） , and the improvement in the observation group was much bet- ter than that in the conti：ol group （P 〈 0.01 ）. The total clinical efficiency in the observation group was umch better than that in the control group （ P 〈 0.05 ） , and ADR occurrence rate in the observation group was muc.h lower than that in the control group （ P 〈 0.05）. Conclusion： Mifepristone combined with misoprostol is a safe and effective method to treat atypical endometrium hyperplasia （AEH）.
出处
《中国药师》
CAS
2014年第3期453-454,共2页
China Pharmacist
